Published in Mol Cell Biol on August 21, 2006
Sirtuins in mammals: insights into their biological function. Biochem J (2007) 7.60
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev (2009) 3.23
Sirtuin 1 and sirtuin 3: physiological modulators of metabolism. Physiol Rev (2012) 1.99
An acetylation/deacetylation-SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol Cell Biol (2007) 1.69
The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res (2009) 1.58
Transcriptional targets of sirtuins in the coordination of mammalian physiology. Curr Opin Cell Biol (2008) 1.57
The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther (2013) 1.57
Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem (2008) 1.46
Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol (2007) 1.43
SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions. Biochim Biophys Acta (2009) 1.41
SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem (2009) 1.33
Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer (2010) 1.32
SIRT3 and cancer: tumor promoter or suppressor? Biochim Biophys Acta (2011) 1.28
The Dachshund gene in development and hormone-responsive tumorigenesis. Trends Endocrinol Metab (2009) 1.28
The p300 acetylase is critical for ligand-activated farnesoid X receptor (FXR) induction of SHP. J Biol Chem (2008) 1.27
Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells. J Biol Chem (2010) 1.24
Aberrant cytoplasm localization and protein stability of SIRT1 is regulated by PI3K/IGF-1R signaling in human cancer cells. Int J Biol Sci (2010) 1.24
SIRT1 in neurodevelopment and brain senescence. Neuron (2014) 1.22
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Epigenetic responses to environmental change and their evolutionary implications. Philos Trans R Soc Lond B Biol Sci (2009) 1.14
Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis (2008) 1.12
Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. Carcinogenesis (2009) 1.11
Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res (2013) 1.09
Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS One (2014) 1.06
Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation. Oncogene (2011) 1.05
Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction. Front Neurol (2013) 1.05
Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle (2009) 1.04
The functional significance of nuclear receptor acetylation. Steroids (2007) 1.04
Corepressive action of CBP on androgen receptor transactivation in pericentric heterochromatin in a Drosophila experimental model system. Mol Cell Biol (2008) 1.04
Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res (2010) 1.02
Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor. J Biol Chem (2013) 1.01
Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle (2013) 1.00
Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation. Cancer Res (2010) 1.00
Biochemical pathways that regulate acetyltransferase and deacetylase activity in mammalian cells. Trends Biochem Sci (2009) 0.99
Sirtuin regulation in aging and injury. Biochim Biophys Acta (2015) 0.98
SIRT1 expression is associated with the chemotherapy response and prognosis of patients with advanced NSCLC. PLoS One (2013) 0.98
SIRT1 represses estrogen-signaling, ligand-independent ERα-mediated transcription, and cell proliferation in estrogen-responsive breast cells. J Endocrinol (2013) 0.98
A high-confidence interaction map identifies SIRT1 as a mediator of acetylation of USP22 and the SAGA coactivator complex. Mol Cell Biol (2013) 0.96
p30 DBC is a potential regulator of tumorigenesis. Cell Cycle (2009) 0.95
Nicotinamide uncouples hormone-dependent chromatin remodeling from transcription complex assembly. Mol Cell Biol (2007) 0.93
Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins. Transl Oncogenomics (2008) 0.93
Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues. Mol Cell Endocrinol (2010) 0.92
Resveratrol inhibits PDGF receptor mitogenic signaling in mesangial cells: role of PTP1B. FASEB J (2008) 0.91
Acetylation in nuclear receptor signaling and the role of sirtuins. Mol Endocrinol (2007) 0.91
Sirtuin 1 (SIRT1) and steroid hormone receptor activity in cancer. J Endocrinol (2011) 0.91
Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev Res (Phila) (2012) 0.90
SirT1 brings stemness closer to cancer and aging. Aging (Albany NY) (2011) 0.90
Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One (2009) 0.90
Acetylation and nuclear receptor action. J Steroid Biochem Mol Biol (2010) 0.89
Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol (2011) 0.89
SIRT1 is a Highly Networked Protein That Mediates the Adaptation to Chronic Physiological Stress. Genes Cancer (2013) 0.89
Sirtuins in epigenetic regulation. Chem Rev (2015) 0.88
The endogenous cell-fate factor dachshund restrains prostate epithelial cell migration via repression of cytokine secretion via a cxcl signaling module. Cancer Res (2015) 0.87
Reciprocal roles of SIRT1 and SKIP in the regulation of RAR activity: implication in the retinoic acid-induced neuronal differentiation of P19 cells. Nucleic Acids Res (2009) 0.87
Unambiguous determination of isobaric histone modifications by reversed-phase retention time and high-mass accuracy. Anal Biochem (2009) 0.87
B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy. J Neurosci Res (2010) 0.85
Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist (2012) 0.85
BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1. Sci Rep (2016) 0.84
SIRT1 expression is associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther (2015) 0.84
Loss of Sirt1 promotes prostatic intraepithelial neoplasia, reduces mitophagy, and delays PARK2 translocation to mitochondria. Am J Pathol (2015) 0.84
Sirtuin biology and relevance to diabetes treatment. Diabetes Manag (Lond) (2012) 0.83
Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells. Mol Endocrinol (2014) 0.83
Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response. Epigenetics Chromatin (2015) 0.82
The sirtuins in the pathogenesis of cancer. Clin Epigenetics (2010) 0.81
Androgen receptor signalling in prostate cancer: the functional consequences of acetylation. J Biomed Biotechnol (2010) 0.80
Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy. CNS Neurol Disord Drug Targets (2013) 0.80
Resveratrol stimulates cortisol biosynthesis by activating SIRT-dependent deacetylation of P450scc. Endocrinology (2012) 0.80
Environmental-stress-induced Chromatin Regulation and its Heritability. J Carcinog Mutagen (2014) 0.78
Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. Oncotarget (2016) 0.77
Sirt1-deficient mice have hypogonadotropic hypogonadism due to defective GnRH neuronal migration. Mol Endocrinol (2014) 0.76
Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo. Asian J Androl (2014) 0.76
Divergent Binding and Transactivation by Two Related Steroid Receptors at the Same Response Element. J Biol Chem (2016) 0.76
Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy. Cancers (Basel) (2017) 0.75
Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells. Cancers (Basel) (2015) 0.75
Better Living through Chemistry: Caloric Restriction (CR) and CR Mimetics Alter Genome Function to Promote Increased Health and Lifespan. Front Genet (2016) 0.75
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature (2000) 20.54
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science (2004) 17.38
hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell (2001) 15.97
Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell (2001) 15.05
The Protein Data Bank. Acta Crystallogr D Biol Crystallogr (2002) 14.44
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. Science (2000) 12.98
The Sir2 family of protein deacetylases. Annu Rev Biochem (2004) 9.28
Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun (2000) 9.09
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. Proc Natl Acad Sci U S A (2000) 7.92
Modeller: generation and refinement of homology-based protein structure models. Methods Enzymol (2003) 7.15
Global histone modification patterns predict risk of prostate cancer recurrence. Nature (2005) 7.03
A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci U S A (2000) 6.49
Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. Nature (2003) 6.25
Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell (2004) 5.37
The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem (2004) 5.37
Substrate-specific activation of sirtuins by resveratrol. J Biol Chem (2005) 5.28
Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell (2003) 5.23
Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell (2001) 4.73
Calorie restriction extends yeast life span by lowering the level of NADH. Genes Dev (2004) 4.51
Classification of prostatic carcinomas. Cancer Chemother Rep (1966) 4.02
Crystal structure of a SIR2 homolog-NAD complex. Cell (2001) 3.57
Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics (2004) 3.35
The molecular biology of the SIR proteins. Gene (2001) 3.05
SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem (2005) 2.59
Role of protein methylation in regulation of transcription. Endocr Rev (2004) 2.57
Chemistry of gene silencing: the mechanism of NAD+-dependent deacetylation reactions. Biochemistry (2001) 2.54
p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem (2000) 2.31
Acetylation of TAF(I)68, a subunit of TIF-IB/SL1, activates RNA polymerase I transcription. EMBO J (2001) 2.24
SIRT1 and endocrine signaling. Trends Endocrinol Metab (2006) 2.17
Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells. EMBO J (1999) 2.10
A CBP/p300 homolog specifies multiple differentiation pathways in Caenorhabditis elegans. Genes Dev (1998) 2.09
Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol Cell (2002) 2.00
The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol (1999) 2.00
Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling. Mol Cell Biol (2006) 1.95
Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem (1997) 1.92
Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol (2003) 1.89
Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res (2003) 1.83
Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol Cell (2005) 1.71
Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol (2001) 1.71
Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem (2004) 1.64
Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Mol Cell Biol (2002) 1.48
Structure and substrate binding properties of cobB, a Sir2 homolog protein deacetylase from Escherichia coli. J Mol Biol (2004) 1.31
Androgen receptor corepressors: an overview. Prostate (2005) 1.25
Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene (2006) 1.21
Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab (1996) 1.15
The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int (2005) 1.15
The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity. J Biol Chem (2004) 1.14
Induction of 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13. Mol Endocrinol (1999) 1.13
Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res (2003) 0.97
Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies. Am J Physiol Endocrinol Metab (2003) 0.96
High activity of mitochondrial glycerophosphate dehydrogenase and glycerophosphate-dependent ROS production in prostate cancer cell lines. Biochem Biophys Res Commun (2005) 0.95
Acetylation in hormone signaling and the cell cycle. Cytokine Growth Factor Rev (2002) 0.87
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet (2012) 10.53
Modes of p53 regulation. Cell (2009) 9.31
Mammalian SIRT1 represses forkhead transcription factors. Cell (2004) 8.89
Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature (2002) 7.71
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell (2007) 6.47
Acetylation is indispensable for p53 activation. Cell (2008) 5.70
Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell (2006) 5.64
p53 ubiquitination: Mdm2 and beyond. Mol Cell (2006) 5.57
Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell (2008) 5.51
Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol (2003) 5.46
SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell (2007) 5.30
Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science (2003) 5.23
Minireview: Cyclin D1: normal and abnormal functions. Endocrinology (2004) 5.22
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science (2013) 5.10
Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses. Cell (2005) 5.04
Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell (2012) 4.96
SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab (2008) 4.89
The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle (2009) 4.69
ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell (2005) 4.60
Non-transcriptional control of DNA replication by c-Myc. Nature (2007) 4.55
Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell (2002) 4.33
Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20
FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction. Cell Metab (2005) 4.14
A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell (2004) 4.05
Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int (2013) 3.97
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem (2006) 3.40
Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem (2002) 3.37
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab (2012) 3.18
How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer (2008) 3.17
Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci U S A (2005) 3.16
Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle (2010) 3.15
An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol (2009) 3.15
Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A (2011) 3.14
Non-invasive prenatal measurement of the fetal genome. Nature (2012) 3.11
Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics (2007) 3.09
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
Parc: a cytoplasmic anchor for p53. Cell (2003) 3.06
Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology (2011) 3.05
A cyclin D1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol (2008) 3.02
Acetylation inactivates the transcriptional repressor BCL6. Nat Genet (2002) 3.00
Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle (2010) 3.00
Matrix remodeling stimulates stromal autophagy, "fueling" cancer cell mitochondrial metabolism and metastasis. Cell Cycle (2011) 2.92
Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle (2011) 2.91
Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat Cell Biol (2006) 2.85
Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle (2010) 2.80
Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol Cell Biol (2005) 2.72
Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. Cell Cycle (2011) 2.68
Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A (2007) 2.67
Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun (2006) 2.65
A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol (2005) 2.64
Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell (2013) 2.61
SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J Biol Chem (2005) 2.59
p53 post-translational modification: deregulated in tumorigenesis. Trends Mol Med (2010) 2.54
Band alignment of rutile and anatase TiO₂. Nat Mater (2013) 2.51
Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Pparγ. Cell (2012) 2.46
Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol (2009) 2.44
Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene (2003) 2.44
The human serum proteome: display of nearly 3700 chromatographically separated protein spots on two-dimensional electrophoresis gels and identification of 325 distinct proteins. Proteomics (2003) 2.41
Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle (2011) 2.39
Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest (2005) 2.38
Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem (2004) 2.37
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway. PLoS Biol (2006) 2.35
Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle (2010) 2.32
Nearly finished genomes produced using gel microdroplet culturing reveal substantial intraspecies genomic diversity within the human microbiome. Genome Res (2013) 2.29
Chemical and toxicological investigations of a previously unknown poisonous European mushroom Tricholoma terreum. Chemistry (2014) 2.27
Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene (2003) 2.27
The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle (2010) 2.26
Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther (2009) 2.25
Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. J Biol Chem (2010) 2.23
Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol (2003) 2.22
Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol (2006) 2.21
E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell (2002) 2.20
ALK5- and TGFBR2-independent role of ALK1 in the pathogenesis of hereditary hemorrhagic telangiectasia type 2. Blood (2007) 2.17
SIRT1 and endocrine signaling. Trends Endocrinol Metab (2006) 2.17
Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol (2002) 2.15
The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox. Cell Cycle (2010) 2.10